iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,380.00
+5.00 (0.11%)
Jul 18, 2025, 3:30 PM KST
-33.03%
Market Cap138.47B
Revenue (ttm)5.69B
Net Income (ttm)-4.25B
Shares Out31.61M
EPS (ttm)-127.45
PE Ration/a
Forward PEn/a
Dividend100.00 (2.28%)
Ex-Dividend DateDec 27, 2024
Volume541,350
Average Volume1,289,812
Open4,380.00
Previous Close4,380.00
Day's Range4,310.00 - 4,500.00
52-Week Range3,350.00 - 7,050.00
Beta0.65
RSI62.07
Earnings DateAug 10, 2025

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 62
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2024, iNtRON Biotechnology's revenue was 6.42 billion, a decrease of -33.05% compared to the previous year's 9.59 billion. Losses were -2.59 billion, -73.27% less than in 2023.

Financial Statements

News

There is no news available yet.